Quoin Pharmaceuticals Releases New Episode in NETHERTON NOW Video Series.

Quoin Pharmaceuticals announced the release of a new video episode in its NETHERTON NOW series, featuring Professor Jemima Mellerio discussing Netherton Syndrome, a rare and life-threatening genetic condition with no current cure. Mellerio emphasizes the complex challenges of the disease, particularly in infants and young children. The series aims to raise awareness about Netherton Syndrome and its impact on patients and families.

Title: Quoin Pharmaceuticals Releases New Video Episode on Netherton Syndrome, Highlighting the Urgency for Effective Treatment

Quoin Pharmaceuticals Ltd. (QNRX) has released a new episode of its NETHERTON NOW video series, featuring Professor Jemima Mellerio, a leading expert in genetic skin diseases. The video, available at [nethertonnow.com](https://nethertonnow.com), focuses on Netherton Syndrome, a rare and life-threatening genetic condition with no current cure. Mellerio, who is a Consultant Dermatologist at St John’s Institute of Dermatology at Guy’s and St Thomas’ NHS Foundation Trust and Honorary Chair of Paediatric Dermatology at King’s College London, discusses the complex challenges of the disease, particularly in infants and young children.

Netherton Syndrome is classified as a skin disease called ichthyosis. It is a genetic condition that affects the skin's appearance and function. Professor Mellerio emphasizes that it is not just a cosmetic issue but a serious medical condition with associated mortality, especially in young babies and small children. The disease requires intensive treatment every day, highlighting the urgent need for more appropriate and targeted treatments.

The release of this video coincides with Quoin’s recent announcement that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for its lead product candidate, QRX003, for the treatment of Netherton Syndrome. This designation, combined with the existing Orphan Drug status from the European Medicines Agency (EMA), underscores the serious and underserved nature of the disease in pediatric patients.

The NETHERTON NOW campaign is an ongoing initiative from Quoin aimed at raising awareness, improving education, and elevating the voices of patients, caregivers, and experts in the field. The video featuring Professor Mellerio serves to highlight the severity of the condition and the critical need for improved therapeutic options.

QRX003 is a topical lotion formulated with a proprietary delivery technology that contains a broad-spectrum serine protease inhibitor. The absence of LEKTI in Netherton patients leads to excessive skin shedding, resulting in a highly porous and compromised skin barrier. QRX003 is designed to promote a more normalized skin-shedding process and the formation of a stronger and more effective skin barrier.

The FDA Rare Pediatric Disease Designation for QRX003 strengthens Quoin’s regulatory position and may qualify the company for a Priority Review Voucher upon potential FDA approval. These vouchers can be used to expedite the review of future products or sold to other companies, often fetching $100-200 million in recent transactions.

Netherton Syndrome represents a highly specialized market with limited competition. The condition is characterized as a life-threatening genetic skin disorder particularly dangerous for infants and children, creating urgency for effective treatments. The current standard of care appears limited to symptomatic management rather than targeted therapies, positioning QRX003 to potentially address a critical unmet need.

While the press release does not provide clinical data or timelines for QRX003's development, the dual regulatory designations suggest Quoin is successfully navigating the regulatory pathway for rare disease drug development. For a small biotech company with a market cap of $6.1 million as of today, these designations provide validation and potentially enhanced market exclusivity—critical factors for maintaining competitive advantage in the rare disease space.

References:
[1] https://www.tradingview.com/news/reuters.com,2025-06-26:newsml_GNX1XZkPy:0-quoin-pharmaceuticals-releases-new-netherton-now-video-featuring-professor-jemima-mellerio-international-expert-in-genetic-skin-diseases/
[2] https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-releases-new-netherton-now-video-featuring-gvdtke2ie4h4.html